https://app.biotechtracker.dev/ https://app.biotechtracker.dev/calendar https://app.biotechtracker.dev/catalysts https://app.biotechtracker.dev/companies https://app.biotechtracker.dev/about https://app.biotechtracker.dev/methodology https://app.biotechtracker.dev/developers https://app.biotechtracker.dev/glossary https://app.biotechtracker.dev/terms https://app.biotechtracker.dev/privacy https://app.biotechtracker.dev/disclaimer https://app.biotechtracker.dev/companies/ABBV https://app.biotechtracker.dev/companies/ACAD https://app.biotechtracker.dev/companies/ALKS https://app.biotechtracker.dev/companies/ALNY https://app.biotechtracker.dev/companies/AMGN https://app.biotechtracker.dev/companies/ARGX https://app.biotechtracker.dev/companies/ARWR https://app.biotechtracker.dev/companies/AXSM https://app.biotechtracker.dev/companies/AZN https://app.biotechtracker.dev/companies/BEAM https://app.biotechtracker.dev/companies/BIIB https://app.biotechtracker.dev/companies/BMRN https://app.biotechtracker.dev/companies/BMY https://app.biotechtracker.dev/companies/BNTX https://app.biotechtracker.dev/companies/CRSP https://app.biotechtracker.dev/companies/CYTK https://app.biotechtracker.dev/companies/DNLI https://app.biotechtracker.dev/companies/EXEL https://app.biotechtracker.dev/companies/GERN https://app.biotechtracker.dev/companies/GILD https://app.biotechtracker.dev/companies/GSK https://app.biotechtracker.dev/companies/HALO https://app.biotechtracker.dev/companies/IMVT https://app.biotechtracker.dev/companies/INCY https://app.biotechtracker.dev/companies/INSM https://app.biotechtracker.dev/companies/IONS https://app.biotechtracker.dev/companies/IOVA https://app.biotechtracker.dev/companies/JAZZ https://app.biotechtracker.dev/companies/JNJ https://app.biotechtracker.dev/companies/KRYS https://app.biotechtracker.dev/companies/KYMR https://app.biotechtracker.dev/companies/LEGN https://app.biotechtracker.dev/companies/LLY https://app.biotechtracker.dev/companies/MDGL https://app.biotechtracker.dev/companies/MRK https://app.biotechtracker.dev/companies/MRNA https://app.biotechtracker.dev/companies/NBIX https://app.biotechtracker.dev/companies/NTLA https://app.biotechtracker.dev/companies/NVAX https://app.biotechtracker.dev/companies/NVO https://app.biotechtracker.dev/companies/NVS https://app.biotechtracker.dev/companies/PCVX https://app.biotechtracker.dev/companies/PFE https://app.biotechtracker.dev/companies/PTCT https://app.biotechtracker.dev/companies/RARE https://app.biotechtracker.dev/companies/REGN https://app.biotechtracker.dev/companies/RXRX https://app.biotechtracker.dev/companies/RYTM https://app.biotechtracker.dev/companies/SMMT https://app.biotechtracker.dev/companies/SNY https://app.biotechtracker.dev/companies/SRPT https://app.biotechtracker.dev/companies/TAK https://app.biotechtracker.dev/companies/TGTX https://app.biotechtracker.dev/companies/UTHR https://app.biotechtracker.dev/companies/VKTX https://app.biotechtracker.dev/companies/VRTX https://app.biotechtracker.dev/events/amgn-other-2026-06-30-three-maritide-phase-3-studies-in-type-2-diabetes-to-start-5019a4de733bef38 https://app.biotechtracker.dev/events/argx-other-2026-06-30-adimanebart-argx-119-registrational-study-start-in-congeni-0a23915a2425b773 https://app.biotechtracker.dev/events/argx-other-2026-06-30-argx-121-anti-iga-phase-2-start-in-iga-nephropathy-3abbc8de6ab7c36d https://app.biotechtracker.dev/events/argx-other-2026-06-30-argx-118-and-argx-125-to-enter-phase-1-in-2026-181ddbbf5e2728dd https://app.biotechtracker.dev/events/bntx-readout-2026-06-30-multiple-pumitamig-combination-data-readouts-expected-in-496fbd2c565bcbdf https://app.biotechtracker.dev/events/crsp-readout-2026-06-30-lp-a-program-ctx320-ctx321-update-expected-in-2026-79335def0430373b https://app.biotechtracker.dev/events/mrna-approval-2026-06-30-mrna-1010-mflusiva-ex-us-approvals-eu-canada-australia-c498238271676576 https://app.biotechtracker.dev/events/pfe-readout-2026-06-30-mevrometostat-mevpro-1-ph3-mcrpc-readout-ea98728fbdbedd1a https://app.biotechtracker.dev/events/pfe-other-2026-06-30-berobenatide-pf-3944-10-phase-3-obesity-studies-to-start-in-e91ad0d450cfdc6c https://app.biotechtracker.dev/events/pfe-other-2026-06-30-pd-1xvegf-pf-4404-pivotal-study-starts-incl-1l-nsclc-4f1a420aab277008 https://app.biotechtracker.dev/events/tak-other-2026-06-30-zasocitinib-regulatory-submissions-in-plaque-psoriasis-us-n-82f94070d74c1b18 https://app.biotechtracker.dev/events/abbv-approval-2026-09-30-fda-decision-skyrizi-subcutaneous-induction-in-crohn-s-042940ef0ab908e1 https://app.biotechtracker.dev/events/acad-readout-2026-09-30-remlifanserin-ph2-radiant-adp-topline-narrowed-to-sept-o-e2499e686ae9d69e https://app.biotechtracker.dev/events/acad-approval-2026-09-30-european-commission-decision-on-trofinetide-daybue-in-r-ef877c0b02907d15 https://app.biotechtracker.dev/events/acad-readout-2026-09-30-trofinetide-japan-ph3-rett-syndrome-topline-oct-2026-mar-2ee955925024fa34 https://app.biotechtracker.dev/events/alny-readout-2026-09-30-aln-2232-phase-1-obesity-data-96f2ecbaf2fb52f5 https://app.biotechtracker.dev/events/alny-readout-2026-09-30-aln-6400-phase-1-hv-and-phase-2-hht-results-in-2h-2026-e6ccbaafd89bbc26 https://app.biotechtracker.dev/events/amgn-readout-2026-09-30-dazodalibep-phase-3-sjogren-s-disease-results-fa8174776da2ef27 https://app.biotechtracker.dev/events/amgn-approval-2026-09-30-ec-decision-on-repatha-label-expansion-for-primary-prev-317ef7f23bef8fb8 https://app.biotechtracker.dev/events/amgn-other-2026-09-30-tezspire-phase-3-eosinophilic-esophagitis-study-completion-477cc2ab4e322e62 https://app.biotechtracker.dev/events/amgn-other-2026-09-30-uplizna-phase-3-cidp-study-initiation-0674a4a33b3a2a30 https://app.biotechtracker.dev/events/arwr-other-2026-09-30-snda-submission-to-fda-for-plozasiran-in-severe-hypertrigl-c0e50ec5fd5b9439 https://app.biotechtracker.dev/events/arwr-readout-2026-09-30-muir-3-phase-3-topline-plozasiran-in-mixed-hyperlipidemi-dc779a381cb8f963 https://app.biotechtracker.dev/events/azn-pdufa-2026-09-30-extended-fda-decision-window-for-camizestrant-serena-6-9f4f090eb24da604 https://app.biotechtracker.dev/events/azn-readout-2026-09-30-phase-3-avanzar-topline-datroway-imfinzi-in-1l-nsclc-9d4bb8ae52846d0d https://app.biotechtracker.dev/events/beam-readout-2026-09-30-updated-beacon-phase-1-2-data-for-risto-cel-by-year-end-23e89fca9b0dcaa3 https://app.biotechtracker.dev/events/beam-readout-2026-09-30-beam-301-initial-clinical-data-in-glycogen-storage-disea-a2a276aa07c8b14b https://app.biotechtracker.dev/events/biib-conference-2026-09-30-litifilimab-amethyst-52-week-phase-2-cle-data-at-eadv-622d0695c7d2b055 https://app.biotechtracker.dev/events/bmy-readout-2026-09-30-phase-3-librexia-stroke-topline-for-milvexian-with-j-j-3e3ec108c85007b5 https://app.biotechtracker.dev/events/bmy-readout-2026-09-30-cobenfy-adept-1-adp-possible-interim-analysis-and-open-la-55cc18a8f55a4d07 https://app.biotechtracker.dev/events/bntx-readout-2026-09-30-gotistobart-bnt316-phase-3-interim-analysis-in-squamous-988531b1a4a1c2c9 https://app.biotechtracker.dev/events/bntx-readout-2026-09-30-bnt113-ahead-merit-phase-3-first-interim-analysis-in-hpv-99eaca89531f7d26 https://app.biotechtracker.dev/events/bntx-other-2026-09-30-planned-bla-filing-for-trastuzumab-pamirtecan-bnt323-a674065f0883272d https://app.biotechtracker.dev/events/crsp-readout-2026-09-30-zugo-cel-ctx112-updates-across-autoimmune-disease-and-im-e6116ef2327d8734 https://app.biotechtracker.dev/events/crsp-readout-2026-09-30-ctx611-phase-2-topline-in-total-knee-arthroplasty-vte-pr-bedc76b8d4eb4a7c https://app.biotechtracker.dev/events/crsp-readout-2026-09-30-ctx310-angptl3-ph1b-clinical-update-shtg-refractory-hype-ccfdfe2b30557daf https://app.biotechtracker.dev/events/cytk-other-2026-09-30-amber-hfpef-cohort-1-ulacamten-enrollment-completion-dc870e30ab44fa54 https://app.biotechtracker.dev/events/dnli-readout-2026-09-30-dnl593-phase-1-2-results-in-ftd-grn-880f3eb068cb48a9 https://app.biotechtracker.dev/events/exel-readout-2026-09-30-stellar-304-phase-3-topline-in-non-clear-cell-rcc-44274daa8fd5f6df https://app.biotechtracker.dev/events/exel-other-2026-09-30-zanzalintinib-phase-2-stellar-202-squamous-nsclc-initiatio-1145d01d1ad0d6a3 https://app.biotechtracker.dev/events/gern-readout-2026-09-30-impactmf-phase-3-interim-analysis-overall-survival-in-re-571fa508809bfd70 https://app.biotechtracker.dev/events/gild-readout-2026-09-30-trodelvy-phase-3-ascent-gyn-update-in-advanced-recurrent-028cd1fcf9a667fa https://app.biotechtracker.dev/events/gild-readout-2026-09-30-phase-2-updates-emvistagrast-swift-ibd-and-edecesertib-c-99859f4de51d0a8c https://app.biotechtracker.dev/events/gild-readout-2026-09-30-gs-3242-long-acting-injectable-insti-higher-dose-cohort-72f8793518b72fd3 https://app.biotechtracker.dev/events/gsk-other-2026-09-30-camlipixant-us-regulatory-submission-planned-for-h2-2026-f76f60bdc97c228c https://app.biotechtracker.dev/events/gsk-readout-2026-09-30-exdensur-depemokimab-phase-iii-ocean-readout-in-egpa-94b67caa44f766f1 https://app.biotechtracker.dev/events/gsk-other-2026-09-30-jemperli-azur-1-us-regulatory-submission-in-dmmr-locally-ad-83840fee6406646b https://app.biotechtracker.dev/events/gsk-pdufa-2026-09-30-fda-decision-on-jemperli-for-dmmr-rectal-cancer-azur-1-c54f95918411ad3d https://app.biotechtracker.dev/events/gsk-readout-2026-09-30-cabotegravir-3x-yearly-prep-phase-iib-extend4m-registrati-ba5980be23ebeb06 https://app.biotechtracker.dev/events/gsk-pdufa-2026-09-30-fda-decision-on-arexvy-for-immunocompromised-adults-18-8fe5554eb75b113b https://app.biotechtracker.dev/events/gsk-approval-2026-09-30-japan-regulatory-decision-on-bepirovirsen-for-chronic-he-b60c8ce9f6390481 https://app.biotechtracker.dev/events/gsk-other-2026-09-30-bexsero-infant-menb-us-submission-blenrep-dreamm-8-china-su-82652063a06a11f1 https://app.biotechtracker.dev/events/gsk-other-2026-09-30-mo-rez-b7-h4-adc-three-additional-phase-iii-starts-in-ovari-c18e9a71d687cd09 https://app.biotechtracker.dev/events/imvt-readout-2026-09-30-imvt-1402-proof-of-concept-topline-in-cutaneous-lupus-cl-c7e26fd6c302d105 https://app.biotechtracker.dev/events/imvt-other-2026-09-30-imvt-1402-difficult-to-treat-ra-registrational-program-upd-7ba677f4b8db6087 https://app.biotechtracker.dev/events/incy-readout-2026-09-30-niktimvo-ruxolitinib-data-in-newly-diagnosed-chronic-gvh-20aaffd9e789b937 https://app.biotechtracker.dev/events/incy-approval-2026-09-30-potential-eu-approval-of-povorcitinib-in-hidradenitis-s-f41d97b6842a2e58 https://app.biotechtracker.dev/events/incy-readout-2026-09-30-inca033989-mutcalr-phase-1-data-in-treatment-naive-myelo-1edea7705cc519cf https://app.biotechtracker.dev/events/incy-other-2026-09-30-incb123667-cdk2-phase-3-first-line-maintenance-ovarian-can-7e381da7b3434fac https://app.biotechtracker.dev/events/insm-approval-2026-09-30-japan-regulatory-decision-on-brensocatib-in-bronchiecta-13c825360c5ffe40 https://app.biotechtracker.dev/events/insm-other-2026-09-30-tpip-phase-3-initiation-in-progressive-pulmonary-fibrosis-b222843b6450c2b6 https://app.biotechtracker.dev/events/insm-other-2026-09-30-arikayce-encore-data-review-with-japan-pmda-for-label-expa-c131c1ea2377f8de https://app.biotechtracker.dev/events/ions-readout-2026-09-30-horizon-phase-3-lp-a-cardiovascular-outcomes-results-for-7aa9a0b18a9f7a67 https://app.biotechtracker.dev/events/iova-approval-2026-09-30-potential-uk-mhra-approval-of-amtagvi-in-advanced-melan-7770592857171d15 https://app.biotechtracker.dev/events/jnj-pdufa-2026-09-30-fda-decision-window-for-imaavy-nipocalimab-in-warm-autoimmu-a71e898a8061ca36 https://app.biotechtracker.dev/events/jnj-readout-2026-09-30-phase-3-librexia-stroke-topline-for-milvexian-with-bms-1ab049d1d593b622 https://app.biotechtracker.dev/events/jnj-readout-2026-09-30-icotyde-icotrokinra-pivotal-phase-3-iconic-psa-data-in-ps-0b40153ca3b6d0e5 https://app.biotechtracker.dev/events/jnj-readout-2026-09-30-inlexzo-tar-200-additional-phase-3-data-in-high-risk-nmib-0f48dbe746d5e350 https://app.biotechtracker.dev/events/jnj-readout-2026-09-30-caplyta-phase-3-readout-in-bipolar-mania-fc5b2b13b8120332 https://app.biotechtracker.dev/events/krys-readout-2026-09-30-kb407-interim-results-in-cystic-fibrosis-488094cd80dbab5e https://app.biotechtracker.dev/events/krys-readout-2026-09-30-kb707-intratumoral-gorlin-syndrome-opal-1-interim-update-64fd44aeb7f0d892 https://app.biotechtracker.dev/events/krys-other-2026-09-30-kb707-inhaled-kyanite-1-final-dose-expansion-cohort-enroll-bd15088c76d86770 https://app.biotechtracker.dev/events/krys-other-2026-09-30-vyjuvek-additional-maa-filings-incl-switzerland-and-austra-ffa1c96b40bed32c https://app.biotechtracker.dev/events/legn-other-2026-09-30-legend-targets-multiple-ind-filings-oncology-autoimmune-st-52abbd32c0b8cae5 https://app.biotechtracker.dev/events/lly-pdufa-2026-09-30-fda-decision-on-tirzepatide-mace-reduction-indication-surpa-aee7941548b931c7 https://app.biotechtracker.dev/events/mrk-readout-2026-09-30-sac-tmt-trofuse-005-endometrial-cancer-detailed-ph3-data-33ba7bc5bfa72a4f https://app.biotechtracker.dev/events/mrna-readout-2026-09-30-mrna-3927-registrational-data-in-propionic-acidemia-8b3c3e9c9cf05b10 https://app.biotechtracker.dev/events/ntla-other-2026-09-30-lonvo-z-bla-submission-and-anticipated-fda-acceptance-in-h-ccb795a27edadb5c https://app.biotechtracker.dev/events/ntla-other-2026-09-30-magnitude-2-phase-3-enrollment-completion-nex-z-in-attrv-p-34c23868a83a154a https://app.biotechtracker.dev/events/nvo-other-2026-09-30-phase-3-starts-oral-zenagamtide-q3-sc-zenagamtide-cvot-and-63eb0284fe6a1378 https://app.biotechtracker.dev/events/nvo-conference-2026-09-30-cagrisema-redefine-9-lower-dose-phase-3-detailed-resul-b154c63123db19dc https://app.biotechtracker.dev/events/nvs-readout-2026-09-30-phase-3-lp-a-horizon-topline-for-pelacarsen-c8a208a034460648 https://app.biotechtracker.dev/events/nvs-readout-2026-09-30-phase-3-remibrutinib-multiple-sclerosis-readout-15f0a67e995cb54c https://app.biotechtracker.dev/events/nvs-readout-2026-09-30-pivotal-del-desiran-data-in-myotonic-dystrophy-type-1-via-81f0a88debb8f891 https://app.biotechtracker.dev/events/nvs-approval-2026-09-30-fda-approval-expected-for-cosentyx-in-polymyalgia-rheuma-f10fde107fe8e92a https://app.biotechtracker.dev/events/nvs-approval-2026-09-30-fda-decision-on-rhapsido-remibrutinib-in-cindu-symptomat-ef19ecaf1ea5d0fd https://app.biotechtracker.dev/events/nvs-other-2026-09-30-rhapsido-remibrutinib-global-filings-across-three-cindu-sub-e0301fed1fefd957 https://app.biotechtracker.dev/events/nvs-approval-2026-09-30-ianalumab-us-approval-launch-in-sjogren-s-disease-expect-3f143eea187b9eb5 https://app.biotechtracker.dev/events/nvs-readout-2026-09-30-rhapsido-remibrutinib-phase-iii-recharge-1-2-readout-in-h-5df1b82bea3e94c1 https://app.biotechtracker.dev/events/nvs-readout-2026-09-30-ianalumab-phase-iii-vayhit-1-readout-in-first-line-itp-50f682045716e844 https://app.biotechtracker.dev/events/nvs-readout-2026-09-30-qcz484-phase-ii-hypertension-interim-readout-ph3-enabling-c6087b16c8edd59c https://app.biotechtracker.dev/events/nvs-readout-2026-09-30-vhb937-phase-ii-astrals-readout-in-als-37bb2756609b002b https://app.biotechtracker.dev/events/nvs-other-2026-09-30-pelacarsen-us-regulatory-submission-in-lp-a-cv-risk-reducti-d375ee73f8f976d1 https://app.biotechtracker.dev/events/nvs-other-2026-09-30-pelabresib-eu-submission-in-myelofibrosis-b7c0f9be7f651075 https://app.biotechtracker.dev/events/nvs-other-2026-09-30-phase-iii-starts-farabursen-in-adpkd-and-remibrutinib-in-fo-f7894c7487122891 https://app.biotechtracker.dev/events/ptct-other-2026-09-30-fda-engagement-on-votoplam-pivot-hd-24-month-results-in-hu-f9da81db1499e7cd https://app.biotechtracker.dev/events/rare-readout-2026-09-30-gtx-102-phase-3-aspire-angelman-topline-now-guided-to-se-87e7595f857e26a5 https://app.biotechtracker.dev/events/rare-other-2026-09-30-gtx-102-phase-2-3-aurora-enrollment-completion-additional-36266f133641ce5f https://app.biotechtracker.dev/events/rare-other-2026-09-30-ux016-gne-myopathy-externally-funded-phase-1-2-study-start-ef6d38c0afa2e79e https://app.biotechtracker.dev/events/rxrx-other-2026-09-30-rec-4881-fda-registrational-path-update-in-fap-02fe6c517c419cbc https://app.biotechtracker.dev/events/rxrx-readout-2026-09-30-rec-1245-phase-1-dose-escalation-data-8e9ed5041b9fc5b5 https://app.biotechtracker.dev/events/rxrx-other-2026-09-30-rec-7735-pi3ka-h1047r-inhibitor-phase-1-2-start-in-solid-t-6a52b457de8bef9d https://app.biotechtracker.dev/events/rytm-other-2026-09-30-setmelanotide-congenital-ho-substudy-enrollment-completion-38e98fa4b6559aab https://app.biotechtracker.dev/events/rytm-other-2026-09-30-rm-718-phase-1-2-part-d-enrollment-completion-in-prader-wi-9a99b2f8a27d35c7 https://app.biotechtracker.dev/events/smmt-readout-2026-09-30-harmoni-3-squamous-cohort-final-pfs-analysis-770134df1ce8f175 https://app.biotechtracker.dev/events/sny-readout-2026-09-30-sarclisa-phase-3-data-in-transplant-eligible-multiple-mye-040aec963d9a855f https://app.biotechtracker.dev/events/sny-other-2026-09-30-efdoralprin-alfa-us-regulatory-submission-in-alpha-1-antitr-01e8a856739c393e https://app.biotechtracker.dev/events/sny-pdufa-2026-09-30-fda-decision-on-fluzone-high-dose-efluelda-for-adults-50-043639748de56131 https://app.biotechtracker.dev/events/sny-approval-2026-09-30-japan-decision-on-dupixent-in-pediatric-chronic-spontane-b1001e64c5976db2 https://app.biotechtracker.dev/events/sny-other-2026-09-30-nexviazyme-us-label-extension-submission-for-infantile-onse-01d7a76a929f1842 https://app.biotechtracker.dev/events/sny-other-2026-09-30-sp0087-rabies-vaccine-eu-decision-and-us-submission-db99ef89f036b95c https://app.biotechtracker.dev/events/srpt-readout-2026-09-30-phase-1-2-mad-cohort-readouts-for-sirna-programs-in-dm1-e5b3c69c71d403f9 https://app.biotechtracker.dev/events/tgtx-conference-2026-09-30-full-phase-3-enhance-trial-results-presentation-iv-br-f0313ec14e9a1c9d https://app.biotechtracker.dev/events/tgtx-readout-2026-09-30-preliminary-phase-1-azer-cel-data-in-progressive-ms-c312e3df71095f66 https://app.biotechtracker.dev/events/uthr-other-2026-09-30-ralinepag-nda-submission-for-pah-95869b7910437a03 https://app.biotechtracker.dev/events/vrtx-readout-2026-09-30-inaxaplin-phase-2-amplified-data-in-amkd-fall-2026-64bb471c0f5208cf https://app.biotechtracker.dev/events/vrtx-readout-2026-09-30-vx-828-next-generation-cf-corrector-study-results-89116aad3f4bcc7e https://app.biotechtracker.dev/events/vrtx-other-2026-09-30-updated-program-timelines-for-zimislecel-and-vx-017-later-90401fa13d0e131d https://app.biotechtracker.dev/events/incy-conference-2026-10-15-incb161734-kras-g12d-phase-1-pdac-crc-combo-data-rapi-0287f5d869e29412 https://app.biotechtracker.dev/events/incy-conference-2026-10-15-incb123667-bevacizumab-recurrent-ovarian-phase-1-effi-c5836f567065be34 https://app.biotechtracker.dev/events/incy-conference-2026-10-15-inca33890-first-line-mss-crc-phase-1-combo-data-at-es-26f8d3d6da070926 https://app.biotechtracker.dev/events/iova-conference-2026-10-15-saratoga-data-oral-presentation-at-esmo-2026-7e59cd6192336354 https://app.biotechtracker.dev/events/iova-conference-2026-10-15-tilvance-301-lifileucel-pembrolizumab-frontline-melan-bddcbe520b4cd4f8 https://app.biotechtracker.dev/events/vrtx-conference-2026-10-15-vertex-cf-portfolio-abstracts-at-north-american-cysti-28d22d4cb48b7935 https://app.biotechtracker.dev/events/rxrx-conference-2026-11-02-rec-4881-tupelo-fap-data-in-presidential-plenary-at-c-549394e7f9221f71 https://app.biotechtracker.dev/events/cytk-pdufa-2026-11-14-pdufa-date-for-aficamten-snda-maple-hcm-monotherapy-vs-met-2c22b4d971e4b62b https://app.biotechtracker.dev/events/smmt-pdufa-2026-11-14-pdufa-date-for-ivonescimab-in-egfr-mutated-nsclc-post-tki-0385d38fb98099b2 https://app.biotechtracker.dev/events/alny-pdufa-2026-11-15-pdufa-cemdisiran-gmg-regeneron-led-alnylam-royalty-f7ffae22f1a5fe8a https://app.biotechtracker.dev/events/gsk-pdufa-2026-11-15-pdufa-for-neladalkib-in-tki-pretreated-alk-nsclc-72c61f56b092b808 https://app.biotechtracker.dev/events/regn-pdufa-2026-11-15-pdufa-target-action-date-for-cemdisiran-in-generalized-mya-bdea0e1a072db2c2 https://app.biotechtracker.dev/events/abbv-pdufa-2026-11-15-estimated-fda-decision-on-rinvoq-for-non-segmental-vitilig-d13c7b16f1506f56 https://app.biotechtracker.dev/events/alks-readout-2026-11-15-vibrance-3-phase-2-completion-in-idiopathic-hypersomnia-acef82efcdf913d6 https://app.biotechtracker.dev/events/alks-other-2026-11-15-snda-submission-for-lumryz-in-idiopathic-hypersomnia-by-ye-02e9a046ec63beea https://app.biotechtracker.dev/events/argx-readout-2026-11-15-empassion-registrational-topline-empasiprubart-in-multif-856d8a7bb6c516cb https://app.biotechtracker.dev/events/argx-other-2026-11-15-argx-124-next-gen-fcrn-to-complete-phase-1-evaluation-by-e-6cf11098a990b292 https://app.biotechtracker.dev/events/arwr-readout-2026-11-15-aro-alk7-additional-ph1-2-obesity-data-in-q4-2026-80981675c9a9d03a https://app.biotechtracker.dev/events/axsm-readout-2026-11-15-engage-phase-3-topline-solriamfetol-in-binge-eating-diso-d82b5f762e4a3660 https://app.biotechtracker.dev/events/azn-pdufa-2026-11-15-pdufa-for-ultomiris-in-iga-nephropathy-a39d23d7f9ff312a https://app.biotechtracker.dev/events/azn-pdufa-2026-11-15-estimated-fda-action-on-gefurulimab-in-generalized-myasthen-ee51a7601c9f9f64 https://app.biotechtracker.dev/events/beam-other-2026-11-15-risto-cel-beam-101-bla-submission-in-sickle-cell-disease-a-bfa83ac4fa0bed8a https://app.biotechtracker.dev/events/biib-readout-2026-11-15-litifilimab-phase-3-topaz-1-and-topaz-2-topline-in-syste-f52ad274530ac410 https://app.biotechtracker.dev/events/bmrn-other-2026-11-15-bmn-351-dmd-program-update-by-year-end-2026-1a623456cf612c4e https://app.biotechtracker.dev/events/bntx-readout-2026-11-15-trastuzumab-pamirtecan-bnt323-dynasty-breast02-primary-a-5ed18f0c8ecf9790 https://app.biotechtracker.dev/events/cytk-other-2026-11-15-snda-filing-for-aficamten-in-non-obstructive-hcm-3fd6f31df03ed068 https://app.biotechtracker.dev/events/incy-readout-2026-11-15-stop-pn1-pn2-phase-3-data-for-povorcitinib-in-prurigo-no-70c751a33dde0219 https://app.biotechtracker.dev/events/incy-readout-2026-11-15-true-hs1-hs2-phase-3-data-for-ruxolitinib-cream-in-mild-4a7bad086c0b765a https://app.biotechtracker.dev/events/iova-readout-2026-11-15-iov-lun-202-nsclc-registrational-program-updates-b80970d24244d90e https://app.biotechtracker.dev/events/krys-readout-2026-11-15-update-kb111-halite-1-hailey-hailey-interim-results-guid-24069e66853674f7 https://app.biotechtracker.dev/events/krys-readout-2026-11-15-kb803-iolite-registrational-topline-in-deb-corneal-abras-d8d3c2a599a09acc https://app.biotechtracker.dev/events/krys-readout-2026-11-15-update-kb407-cf-interim-results-guided-before-year-end-2-d44887af2a48a77d https://app.biotechtracker.dev/events/krys-other-2026-11-15-kb407-fda-alignment-on-cf-registrational-study-design-expe-05dcaf059cfd7d10 https://app.biotechtracker.dev/events/krys-other-2026-11-15-kb801-emerald-1-neurotrophic-keratitis-enrollment-60-pts-c-90f460bb64cb4b69 https://app.biotechtracker.dev/events/kymr-readout-2026-11-15-kt-621-broaden2-phase-2b-topline-data-in-atopic-dermatit-77396fc4c7ae4cb4 https://app.biotechtracker.dev/events/kymr-readout-2026-11-15-kt-579-phase-1-healthy-volunteer-data-0a096e019965b9af https://app.biotechtracker.dev/events/mdgl-other-2026-11-15-ervogastat-resmetirom-drug-drug-interaction-study-start-4bec13298f0d132b https://app.biotechtracker.dev/events/nvo-pdufa-2026-11-15-expected-fda-decision-on-cagrisema-for-weight-management-c2b36c29cba1e661 https://app.biotechtracker.dev/events/nvo-pdufa-2026-11-15-fda-decision-on-ozempic-pill-25-mg-dose-oral-semaglutide-in-537616f31686c1f4 https://app.biotechtracker.dev/events/nvo-pdufa-2026-11-15-fda-decision-on-sogroya-for-turner-syndrome-ba1f4cc765ddd611 https://app.biotechtracker.dev/events/nvo-other-2026-11-15-etavopivat-us-and-eu-submissions-in-sickle-cell-disease-471a8ad369426192 https://app.biotechtracker.dev/events/nvo-readout-2026-11-15-efruxifermin-phase-3-synchrony-real-world-safety-results-7b195b17220f3831 https://app.biotechtracker.dev/events/pcvx-readout-2026-11-15-opus-1-phase-3-pivotal-topline-for-vax-31-in-adults-e55448fa19f31daf https://app.biotechtracker.dev/events/pfe-pdufa-2026-11-15-pdufa-for-talzenna-xtandi-in-hrr-mutated-mcspc-ed6df08a2ee29393 https://app.biotechtracker.dev/events/pfe-pdufa-2026-11-15-estimated-pdufa-for-tukysa-combination-in-her2-metastatic-b-a43a7bb380a0d108 https://app.biotechtracker.dev/events/pfe-other-2026-11-15-35-valent-pneumococcal-vaccine-adult-candidate-to-enter-cli-63f1eae776aa4e88 https://app.biotechtracker.dev/events/rare-readout-2026-11-15-cyprus2-dose-finding-data-for-ux701-in-wilson-disease-0440177cf7e50dad https://app.biotechtracker.dev/events/rytm-approval-2026-11-15-update-japan-mhlw-decision-on-imcivree-for-acquired-ho-7ee78b15096998b4 https://app.biotechtracker.dev/events/rytm-other-2026-11-15-update-bivamelagon-pivotal-phase-3-in-acquired-ho-to-start-d5468463faa38802 https://app.biotechtracker.dev/events/srpt-other-2026-11-15-elevidys-endeavor-cohort-8-full-enrollment-expected-by-yea-c55d780db7d63845 https://app.biotechtracker.dev/events/tgtx-readout-2026-11-15-subcutaneous-briumvi-phase-3-topline-now-year-end-2026-o-708d984bce7c0c7e https://app.biotechtracker.dev/events/uthr-other-2026-11-15-nda-submission-for-treprostinil-smi-soft-mist-inhaler-by-y-9e39c0b7fb33d9f9 https://app.biotechtracker.dev/events/vktx-other-2026-11-15-initiation-of-phase-3-program-for-oral-vk2735-57219ff1f466b23a https://app.biotechtracker.dev/events/vrtx-readout-2026-11-15-inaxaplin-phase-3-amplitude-interim-analysis-in-amkd-5a0e098daefc242c https://app.biotechtracker.dev/events/vrtx-other-2026-11-15-suzetrigine-dpn-phase-3-enrollment-completion-by-end-of-20-4c0307691cd7f91a https://app.biotechtracker.dev/events/sny-pdufa-2026-11-25-pdufa-for-venglustat-in-type-3-gaucher-disease-4ff316550f1386f2 https://app.biotechtracker.dev/events/vrtx-pdufa-2026-11-30-pdufa-date-for-povetacicept-accelerated-approval-in-iga-ne-4b983368e811d09b https://app.biotechtracker.dev/events/exel-pdufa-2026-12-03-pdufa-date-for-zanzalintinib-atezolizumab-in-metastatic-co-d8e062cea901dc85 https://app.biotechtracker.dev/events/tak-other-2026-12-11-takeda-capital-markets-day-in-tokyo-8fce6e1ff695fb52 https://app.biotechtracker.dev/events/gild-pdufa-2026-12-23-pdufa-date-for-anito-cel-in-4l-relapsed-refractory-multipl-8ca721011ad5dd86 https://app.biotechtracker.dev/events/gild-pdufa-2027-02-02-pdufa-date-for-once-weekly-oral-yeztugo-lenacapavir-for-hi-4ca4a23badc4477f https://app.biotechtracker.dev/events/bmy-readout-2027-02-15-librexia-af-milvexian-ph3-af-stroke-prevention-readout-no-1379a8757f2e0034 https://app.biotechtracker.dev/events/halo-approval-2027-02-15-fda-decision-on-rybrevant-faspro-enhanze-sbla-in-head-a-099b35875aba20d1 https://app.biotechtracker.dev/events/incy-approval-2027-02-15-potential-u-s-approval-of-povorcitinib-in-hidradenitis-e62c185f5a7fbca2 https://app.biotechtracker.dev/events/incy-approval-2027-02-15-potential-u-s-approval-of-tafasitamab-in-first-line-dlb-02c24f484d116dbb https://app.biotechtracker.dev/events/lly-other-2027-02-15-retatrutide-us-regulatory-submission-for-obesity-planned-q1-16c186585cb0bce7 https://app.biotechtracker.dev/events/nvo-pdufa-2027-02-15-fda-decision-on-mash-label-essence-for-wegovy-pill-22df38ce94d27bc6 https://app.biotechtracker.dev/events/srpt-readout-2027-02-15-endeavor-cohort-8-12-week-data-for-elevidys-with-immunos-1ae1fe49f73ffdfa https://app.biotechtracker.dev/events/bmrn-pdufa-2027-02-28-pdufa-date-for-voxzogo-full-approval-snda-in-achondroplasi-dc56985f8c4311c6 https://app.biotechtracker.dev/events/srpt-pdufa-2027-02-28-pdufa-date-for-amondys-45-and-vyondys-53-sndas-conversion-9c1532abe05d9797 https://app.biotechtracker.dev/events/amgn-readout-2027-03-30-maritide-phase-3-maritime-1-and-maritime-2-obesity-topli-7f421c5f8b02672f https://app.biotechtracker.dev/events/argx-readout-2027-03-30-advance-next-registrational-topline-efgartigimod-in-prim-7a5bfce7ae25d42d https://app.biotechtracker.dev/events/arwr-other-2027-03-30-zodasiran-ph3-yosemite-hofh-study-completion-mid-2027-ad9c24383794db74 https://app.biotechtracker.dev/events/azn-readout-2027-03-30-laroprovstat-oral-pcsk9-first-phase-iii-data-in-h1-2027-4ca5c4b45b03dcdd https://app.biotechtracker.dev/events/biib-readout-2027-03-30-litifilimab-phase-3-cutaneous-lupus-cle-data-ab286013607b2382 https://app.biotechtracker.dev/events/biib-readout-2027-03-30-felzartamab-phase-3-transcend-data-in-antibody-mediated-01712115946b2ed7 https://app.biotechtracker.dev/events/bmy-readout-2027-03-30-cobenfy-adept-alzheimer-s-psychosis-readouts-begin-early-79dca924ffab389c https://app.biotechtracker.dev/events/dnli-readout-2027-03-30-beacon-phase-2a-data-for-dnl151-in-lrrk2-variant-parkins-638c122879d79f90 https://app.biotechtracker.dev/events/dnli-readout-2027-03-30-dnl628-alzheimer-s-disease-study-data-995642076d356117 https://app.biotechtracker.dev/events/gsk-pdufa-2027-03-30-fda-decision-on-3x-yearly-cabotegravir-for-hiv-prep-c49b39e4944ecce5 https://app.biotechtracker.dev/events/gsk-approval-2027-03-30-eu-and-china-regulatory-decisions-on-bepirovirsen-for-ch-e60e5cadeab43524 https://app.biotechtracker.dev/events/gsk-other-2027-03-30-exdensur-egpa-submissions-us-eu-cn-jp-and-jideytro-1l-ros1-45e2076349da0b3e https://app.biotechtracker.dev/events/halo-other-2027-03-30-first-hypercon-platform-clinical-trial-starts-3a0b2cb05c09a498 https://app.biotechtracker.dev/events/incy-other-2027-03-30-povorcitinib-vitiligo-regulatory-submissions-planned-2e02355ccd92068a https://app.biotechtracker.dev/events/insm-other-2027-03-30-tpip-phase-3-initiation-in-idiopathic-pulmonary-fibrosis-942636888599fcbf https://app.biotechtracker.dev/events/iova-approval-2027-03-30-potential-switzerland-swissmedic-approval-of-amtagvi-64b745109eb8f2da https://app.biotechtracker.dev/events/iova-readout-2027-03-30-initial-lifileucel-data-in-cutaneous-scc-and-merkel-cell-70afe68273dbb406 https://app.biotechtracker.dev/events/jazz-readout-2027-03-30-modeyso-action-phase-3-interim-os-analysis-104939b921de88e5 https://app.biotechtracker.dev/events/krys-readout-2027-03-30-kb707-kyanite-1-updated-interim-results-in-nsclc-e3a6414d28805010 https://app.biotechtracker.dev/events/kymr-other-2027-03-30-kt-621-phase-3-initiation-in-atopic-dermatitis-330da43de409d68f https://app.biotechtracker.dev/events/ntla-approval-2027-03-30-anticipated-u-s-approval-launch-of-lonvo-z-in-hereditar-f2df27e4f27d99c0 https://app.biotechtracker.dev/events/nvax-other-2027-03-30-nuvaxovid-manufacturing-tech-transfer-to-sanofi-completion-442270044568494c https://app.biotechtracker.dev/events/nvo-approval-2027-03-30-eu-and-japan-decisions-on-sogroya-for-turner-syndrome-a5496a1b7195fa72 https://app.biotechtracker.dev/events/nvs-approval-2027-03-30-del-zota-dmd44-us-launch-expected-h1-2027-subject-to-fda-8eb84076b3279b12 https://app.biotechtracker.dev/events/nvs-readout-2027-03-30-zigakibart-phase-iii-beyond-readout-in-iga-nephropathy-b26c518675940d00 https://app.biotechtracker.dev/events/pcvx-readout-2027-03-30-opus-2-and-opus-3-phase-3-data-for-vax-31-in-adults-a454e88389200ebd https://app.biotechtracker.dev/events/rare-readout-2027-03-30-enh3ance-phase-3-second-primary-endpoint-data-for-dtx301-1bf8a483b328f117 https://app.biotechtracker.dev/events/rxrx-readout-2027-03-30-rec-617-phase-1-combination-safety-pk-data-1d0f7bc4d6c0c287 https://app.biotechtracker.dev/events/rxrx-readout-2027-03-30-rec-3565-phase-1-monotherapy-safety-pk-data-b24d8e71b829f025 https://app.biotechtracker.dev/events/smmt-readout-2027-03-30-harmoni-3-non-squamous-cohort-pfs-analysis-25803ac181671b48 https://app.biotechtracker.dev/events/tak-other-2027-03-30-zasocitinib-psoriasis-us-filing-in-fy2026-launch-targeted-h-a35716f04bb39a52 https://app.biotechtracker.dev/events/vrtx-readout-2027-03-30-inaxaplin-amplitude-phase-2-3-interim-analysis-data-in-e-81b86103a39a058e https://app.biotechtracker.dev/events/axsm-pdufa-2027-05-01-pdufa-date-for-axs-12-in-cataplexy-associated-with-narcole-2d96d45137de8f35 https://app.biotechtracker.dev/events/bmy-pdufa-2027-05-13-pdufa-mezigdomide-carfilzomib-dex-mezikd-in-rrmm-c1bb806072abc29d https://app.biotechtracker.dev/events/arwr-other-2027-05-15-potential-accelerated-redemplo-shtg-launch-q2-2027-prv-pri-f5d2764ef7a49b3d https://app.biotechtracker.dev/events/abbv-readout-2027-06-30-abbv-1758-brain-shuttle-alzheimer-s-antibody-data-expect-22438216e6e3b647 https://app.biotechtracker.dev/events/alks-readout-2027-06-30-brilliance-phase-3-studies-completion-in-narcolepsy-nt1-415e8aef6ededc9a https://app.biotechtracker.dev/events/argx-other-2027-06-30-vyvgart-sc-autoinjector-launch-for-all-approved-indication-5b7ab78bf97a3a54 https://app.biotechtracker.dev/events/axsm-readout-2027-06-30-sustain-phase-3-topline-solriamfetol-in-shift-work-disor-5687b703cfb9bc0a https://app.biotechtracker.dev/events/bmrn-readout-2027-06-30-bmn-333-long-acting-cnp-phase-2-3-achondroplasia-data-up-b0d552b2ce6e47b7 https://app.biotechtracker.dev/events/bmrn-approval-2027-06-30-potential-fda-approval-launch-of-voxzogo-in-hypochondro-9617758342743ab8 https://app.biotechtracker.dev/events/bmy-readout-2027-06-30-phase-3-librexia-af-topline-for-milvexian-delayed-to-2027-c51d6bce6bb121fa https://app.biotechtracker.dev/events/dnli-other-2027-06-30-dnl126-bla-submission-and-potential-accelerated-approval-i-84e423a03d4b97bb https://app.biotechtracker.dev/events/dnli-readout-2027-06-30-dnl593-ftd-grn-phase-1-2-results-pushed-to-2027-b2b27fdfe16523ed https://app.biotechtracker.dev/events/dnli-readout-2027-06-30-dnl952-etv-gaa-pompe-disease-initial-clinical-data-2e9d5c76fa94f94b https://app.biotechtracker.dev/events/dnli-readout-2027-06-30-dnl921-atv-abeta-alzheimer-s-phase-1-1b-safety-and-proof-32c8f7d121bd2857 https://app.biotechtracker.dev/events/gild-other-2027-06-30-islatravir-lenacapavir-once-weekly-oral-hiv-regimen-filing-ae9be7fc7cb10806 https://app.biotechtracker.dev/events/gild-other-2027-06-30-anito-cel-potential-filing-in-second-line-multiple-myeloma-918311a05432de8e https://app.biotechtracker.dev/events/gild-readout-2027-06-30-purpose-365-once-yearly-lenacapavir-prep-update-1cda6f6b207c633e https://app.biotechtracker.dev/events/gsk-readout-2027-06-30-ris-rez-b7-h3-adc-global-phase-iii-embold-sclc-301-pivota-34d86435a802319d https://app.biotechtracker.dev/events/imvt-readout-2027-06-30-imvt-1402-registrational-topline-in-graves-disease-c217c8fba09ca2d1 https://app.biotechtracker.dev/events/ions-approval-2027-06-30-potential-eu-approval-launch-of-olezarsen-for-shtg-e8288f3c3345affc https://app.biotechtracker.dev/events/iova-other-2027-06-30-amtagvi-sbla-submission-in-nonsquamous-nsclc-iov-lun-202-4455fe65af213026 https://app.biotechtracker.dev/events/jnj-readout-2027-06-30-phase-3-librexia-af-topline-for-milvexian-delayed-to-2027-20281306d04a0491 https://app.biotechtracker.dev/events/krys-readout-2027-06-30-kb408-aatd-lung-disease-interim-results-in-2027-60cbd410b6164436 https://app.biotechtracker.dev/events/kymr-other-2027-06-30-gilead-ind-filing-for-kt-200-cdk2-degrader-63bf76c3cb738a24 https://app.biotechtracker.dev/events/legn-readout-2027-06-30-cartitude-5-and-cartitude-6-event-driven-phase-3-readout-9668ef828cc34460 https://app.biotechtracker.dev/events/mdgl-readout-2027-06-30-maestro-nash-outcomes-phase-3-topline-rezdiffra-in-compe-19b6f730c5c1f680 https://app.biotechtracker.dev/events/nvax-other-2027-06-30-novavax-c-difficile-vaccine-clinical-entry-as-early-as-202-781d547f0a44313e https://app.biotechtracker.dev/events/nvs-readout-2027-06-30-ianalumab-phase-iii-readouts-in-sle-and-lupus-nephritis-f6d8979d818d80a8 https://app.biotechtracker.dev/events/nvs-readout-2027-06-30-leqvio-cardiovascular-outcomes-trials-victorion-2-prevent-d1f280342c8e5094 https://app.biotechtracker.dev/events/nvs-readout-2027-06-30-kesimpta-every-two-month-maintenance-dosing-phase-iii-rea-094a7ade9d7e88d4 https://app.biotechtracker.dev/events/ptct-other-2027-06-30-ptc303-msh3-splicing-clinical-entry-c5f5d5cdc42b49b1 https://app.biotechtracker.dev/events/sny-readout-2027-06-30-frexalimab-phase-3-data-in-relapsing-multiple-sclerosis-f-300eafd7d44bf182 https://app.biotechtracker.dev/events/sny-approval-2027-06-30-eu-and-japan-decisions-on-venglustat-for-type-3-gaucher-dcf82f1e67631099 https://app.biotechtracker.dev/events/sny-readout-2027-06-30-phase-2-readouts-brivekimig-in-hs-and-lunsekimig-in-high-33d8ee32cd8c7bf4 https://app.biotechtracker.dev/events/sny-readout-2027-06-30-fitusiran-phase-3-data-in-hemophilia-a-b-12-years-and-eu-c702bf33d7d73b8b https://app.biotechtracker.dev/events/sny-readout-2027-06-30-riliprubart-phase-3-data-in-cidp-and-us-eu-submissions-6403559ac46cef79 https://app.biotechtracker.dev/events/sny-other-2027-06-30-sarclisa-transplant-eligible-ndmm-us-submission-sarclisa-sc-d52e5f7d5f6e9a9c https://app.biotechtracker.dev/events/sny-other-2027-06-30-myqorzo-nhcm-and-redemplo-shtg-china-submissions-f2233f665146616a https://app.biotechtracker.dev/events/sny-readout-2027-06-30-sp0202-pneumococcal-and-sp0218-yellow-fever-vaccine-phase-2b7647dc75ca3f8d https://app.biotechtracker.dev/events/uthr-approval-2027-06-30-fda-action-expected-on-tyvaso-ipf-snda-c49107e62031c6a0 https://app.biotechtracker.dev/events/uthr-approval-2027-06-30-potential-fda-approval-of-ralinepag-tablets-in-pah-e0c1ebfc00d44646 https://app.biotechtracker.dev/events/vktx-readout-2027-06-30-vanquish-1-and-vanquish-2-phase-3-topline-subcutaneous-v-4b58c608dd80d1e6 https://app.biotechtracker.dev/events/argx-readout-2027-09-30-unity-registrational-topline-efgartigimod-in-sjogren-s-d-cf8d65ba4f0ec105 https://app.biotechtracker.dev/events/argx-readout-2027-09-30-emvigorate-and-emnergize-registrational-topline-empasipr-992da0da0887611b https://app.biotechtracker.dev/events/ions-readout-2027-09-30-reveal-phase-3-data-for-obudanersen-in-angelman-syndrome-b853286db125bbcd https://app.biotechtracker.dev/events/kymr-readout-2027-09-30-kt-621-breadth-phase-2b-asthma-data-f856e5531c494a8e https://app.biotechtracker.dev/events/nbix-readout-2027-09-30-phase-3-topline-data-for-osavampator-in-major-depressive-67b0e3ca0ed727d4 https://app.biotechtracker.dev/events/nbix-readout-2027-09-30-first-phase-3-readout-for-direclidine-nbi-1117568-in-sch-d08cf347f743a636 https://app.biotechtracker.dev/events/pcvx-readout-2027-09-30-vax-a1-phase-1-topline-in-adults-8801de50e36032ff https://app.biotechtracker.dev/events/regn-approval-2027-09-30-european-commission-decision-on-cemdisiran-in-gmg-120c07741a1adaa6 https://app.biotechtracker.dev/events/rxrx-readout-2027-09-30-rec-4539-phase-1-monotherapy-safety-pk-data-b6483b66420f28ff https://app.biotechtracker.dev/events/uthr-readout-2027-09-30-teton-ppf-phase-3-topline-in-progressive-pulmonary-fibro-a2884c164a4fbcbc https://app.biotechtracker.dev/events/sny-readout-2028-06-30-wayrilz-phase-3-data-in-igg4-rd-and-waiha-with-us-eu-subm-0edd794fe766933e https://app.biotechtracker.dev/events/mrk-conference-2026-10-26-merck-oncology-investor-event-at-esmo-2026-madrid-a8aab1c0b859bc97 https://app.biotechtracker.dev/events/ions-pdufa-2026-10-26-pdufa-date-for-bepirovirsen-in-chronic-hepatitis-b-gsk-par-81b1b0a16fb33f86 https://app.biotechtracker.dev/events/gsk-pdufa-2026-10-26-pdufa-for-bepirovirsen-in-chronic-hepatitis-b-6df3d53608eaa715 https://app.biotechtracker.dev/events/alny-other-2026-10-26-alnylam-rnai-roundtable-on-aln-htt02-huntington-s-9b608f7e3e365063 https://app.biotechtracker.dev/events/alny-readout-2026-10-23-aln-htt02-phase-1-initial-results-in-huntington-s-diseas-ebd3d01e499eb6e1 https://app.biotechtracker.dev/events/mrk-pdufa-2026-10-10-pdufa-for-ifinatamab-deruxtecan-in-previously-treated-es-sc-a472c4b830cacab2 https://app.biotechtracker.dev/events/mrk-pdufa-2026-10-04-pdufa-welireg-lenvima-litespark-011-previously-treated-adva-9552f2fb5da4c300 https://app.biotechtracker.dev/events/pfe-pdufa-2026-09-30-pdufa-for-brepocitinib-in-dermatomyositis-priovant-pfizer-p-d15d053200d021f4 https://app.biotechtracker.dev/events/nvo-pdufa-2026-09-30-estimated-fda-action-date-for-mim8-denecimig-in-hemophilia-8028efb225020632 https://app.biotechtracker.dev/events/ions-pdufa-2026-09-22-pdufa-date-for-zilganersen-in-alexander-disease-4a0d61dcd0fb6470 https://app.biotechtracker.dev/events/mrk-pdufa-2026-09-21-pdufa-for-winrevair-label-update-based-on-phase-3-hyperion-6b63bde1a9568bc5 https://app.biotechtracker.dev/events/rare-pdufa-2026-09-19-pdufa-date-for-ux111-gene-therapy-in-sanfilippo-syndrome-t-2e9bb8175e132493 https://app.biotechtracker.dev/events/alny-other-2026-09-17-alnylam-rnai-roundtable-on-zilebesiran-hypertension-c3e5df0093d0b824 https://app.biotechtracker.dev/events/bntx-conference-2026-09-15-pumitamig-elfetabart-drozuntecan-late-breaking-oral-a-fe9f6b944d4d1055 https://app.biotechtracker.dev/events/bntx-conference-2026-09-14-gotistobart-preserve-003-stage-1-updated-os-mini-oral-15f4f314a47455c5 https://app.biotechtracker.dev/events/beam-conference-2026-09-08-beam-302-aatd-late-breaking-oral-at-ers-2026-on-sept-f8d2a5c3e40bf38f https://app.biotechtracker.dev/events/nvs-conference-2026-08-31-leqvio-victorion-challenge-vs-bempedoic-acid-late-brea-e578540bf870f70c https://app.biotechtracker.dev/events/arwr-conference-2026-08-30-shasta-3-shasta-4-detailed-phase-3-results-esc-congre-dc58d20fb6186851 https://app.biotechtracker.dev/events/nvs-conference-2026-08-29-tranquility-pacibekitug-anti-il-6-ckd-inflammation-dat-35f8ce3f437131ab https://app.biotechtracker.dev/events/cytk-conference-2026-08-29-maple-hcm-aficamten-vs-metoprolol-late-breaker-at-esc-51e7e29775246d6c https://app.biotechtracker.dev/events/ions-conference-2026-08-28-tryngolza-core-ole-one-year-shtg-extension-data-oral-abef2fe8a45bf7f6 https://app.biotechtracker.dev/events/ions-conference-2026-08-28-ion775-phase-1-12-month-single-dose-htg-data-oral-at-a2ff6c55e7d7b85b https://app.biotechtracker.dev/events/cytk-conference-2026-08-28-acacia-hcm-aficamten-nhcm-primary-results-hot-line-at-eb203a526fdbbf40 https://app.biotechtracker.dev/events/crsp-conference-2026-08-28-ctx310-durability-late-breaker-at-esc-congress-2026-70dbe576f1648da3 https://app.biotechtracker.dev/events/gild-pdufa-2026-08-27-pdufa-for-bictegravir-lenacapavir-bic-len-once-daily-hiv-s-4df3ec1f6f1170eb https://app.biotechtracker.dev/events/jazz-pdufa-2026-08-25-pdufa-date-for-ziihera-zanidatamab-in-first-line-her2-gea-e0d5b5eb5f9474aa https://app.biotechtracker.dev/events/rare-pdufa-2026-08-23-pdufa-date-for-dtx401-gene-therapy-in-glycogen-storage-dis-6329954787c2a02c https://app.biotechtracker.dev/events/regn-approval-2026-08-19-fda-approves-pasatru-garetosmab-for-fibrodysplasia-ossi-192f4e0c1d715da6 https://app.biotechtracker.dev/events/rare-approval-2026-08-19-fda-accelerated-approval-of-genglycos-dtx401-for-gsdia-14eeb4cb028463c5 https://app.biotechtracker.dev/events/nvs-conference-2026-08-19-novartis-sets-out-10-cardiovascular-abstracts-for-esc-0b0dea130285774a https://app.biotechtracker.dev/events/mrna-readout-2026-08-19-first-positive-phase-3-readout-for-an-mrna-cancer-therap-932f2427a131f067 https://app.biotechtracker.dev/events/mrk-readout-2026-08-19-phase-3-interpath-001-met-rfs-and-dmfs-endpoints-in-resec-3e05a7362eef2fa2 https://app.biotechtracker.dev/events/azn-readout-2026-08-17-phase-3-destiny-lung04-enhertu-improved-pfs-in-first-line-7eff5f45ff483381 https://app.biotechtracker.dev/events/azn-readout-2026-08-17-phase-3-evolve-lung02-discontinued-volrustomig-unlikely-t-17ba4442cebfbe43 https://app.biotechtracker.dev/events/azn-readout-2026-08-17-phase-3-saffron-tagrisso-plus-orpathys-improved-pfs-and-o-08063d50c2d61e2f https://app.biotechtracker.dev/events/argx-readout-2026-08-17-phase-3-alkivia-met-primary-endpoint-in-autoimmune-myosi-2f2fef9f35d2c1c7 https://app.biotechtracker.dev/events/bmy-approval-2026-08-13-fda-grants-accelerated-approval-to-zenbexus-first-celmod-570e52ef4d1bebb1 https://app.biotechtracker.dev/events/smmt-approval-2026-08-12-china-nmpa-approves-ivonescimab-chemo-for-1l-squamous-n-80217841189d7da4 https://app.biotechtracker.dev/events/rytm-approval-2026-08-11-uk-mhra-expands-imcivree-authorization-to-acquired-hypo-d5435560d5171a63 https://app.biotechtracker.dev/events/iova-other-2026-08-06-fda-grants-fast-track-to-lifileucel-in-soft-tissue-sarcoma-0b6528a4cc67d16d https://app.biotechtracker.dev/events/rytm-readout-2026-08-04-rm-718-phase-2-11-6-mean-bmi-reduction-at-week-16-in-acq-d5ef893582558274 https://app.biotechtracker.dev/events/nvs-approval-2026-07-31-fda-approves-pluvicto-plus-arpi-for-psma-metastatic-horm-78ad70dc65f92757 https://app.biotechtracker.dev/events/nvo-readout-2026-07-31-ziltivekimab-misses-primary-mace-endpoint-in-phase-3-zeus-6f7ac33989763b67 https://app.biotechtracker.dev/events/mrna-readout-2026-07-31-phase-3-norovirus-vaccine-mrna-1403-missed-early-success-6af7095f1c4ab0bc https://app.biotechtracker.dev/events/pfe-readout-2026-07-30-two-phase-3-litfulo-vitiligo-trials-met-co-primary-endpoi-302cef9f797e1a08 https://app.biotechtracker.dev/events/cytk-approval-2026-07-30-uk-mhra-grants-myqorzo-aficamten-marketing-authorisatio-23e7cb8c1c41ea22 https://app.biotechtracker.dev/events/bntx-approval-2026-07-29-european-commission-authorizes-xfg-adapted-covid-19-vac-8d124f86de19f447 https://app.biotechtracker.dev/events/amgn-other-2026-07-29-chmp-backs-broader-repatha-use-before-a-first-heart-attack-618ee50d53fe0606 https://app.biotechtracker.dev/events/gsk-readout-2026-07-28-second-phase-iii-win-artemis-011-met-pfs-endpoint-for-ris-e9059250ad524868 https://app.biotechtracker.dev/events/sny-other-2026-07-24-sanofi-discontinues-amlitelimab-in-atopic-dermatitis-will-n-ce184871e53860b9 https://app.biotechtracker.dev/events/lly-readout-2026-07-23-phase-3-triumph-2-and-triumph-3-met-primary-endpoints-for-338da5d5a8acabc0 https://app.biotechtracker.dev/events/jnj-readout-2026-07-23-monumental-6-tecvayli-talvey-cut-progression-or-death-ris-2709b2bd7dbe0a0b https://app.biotechtracker.dev/events/abbv-readout-2026-07-23-epcore-dlbcl-1-us-primary-endpoint-of-overall-survival-w-0a4f0272624ccd3f https://app.biotechtracker.dev/events/acad-other-2026-07-20-fda-grants-fast-track-to-remlifanserin-for-alzheimer-s-dis-8ede29d26464f09f https://app.biotechtracker.dev/events/nvs-approval-2026-07-17-fda-grants-fabhalta-traditional-approval-to-slow-kidney-96ddcfd70384580b https://app.biotechtracker.dev/events/gsk-readout-2026-07-17-camlipixant-calm-1-2-phase-iii-miss-gsk-halts-chronic-cou-86af0fe9e75b8fa6 https://app.biotechtracker.dev/events/tak-conference-2026-07-16-zasocitinib-phase-3-secondary-endpoints-show-clearance-87c59a23e89ef90f https://app.biotechtracker.dev/events/mrk-approval-2026-07-16-fda-approves-lipfendra-enlicitide-first-once-daily-oral-4434615ede68d294 https://app.biotechtracker.dev/events/insm-readout-2026-07-16-tpip-open-label-extension-sustained-12-month-benefit-in-8d8345593fa34e43 https://app.biotechtracker.dev/events/axsm-other-2026-07-15-fda-accepts-axs-12-nda-for-cataplexy-in-narcolepsy-pdufa-m-e60212d2084edabc https://app.biotechtracker.dev/events/alny-conference-2026-07-15-mivelsiran-phase-1-eoad-data-and-phase-2-down-syndrom-b73198f40d52e910 https://app.biotechtracker.dev/events/biib-conference-2026-07-14-diranersen-phase-2-celia-data-at-aaic-biogen-to-advan-a5b69da3734bc594 https://app.biotechtracker.dev/events/gsk-readout-2026-07-13-jemperli-azur-1-met-primary-endpoint-in-dmmr-msi-h-locall-a7e045e76579076e https://app.biotechtracker.dev/events/biib-approval-2026-07-13-fda-approves-leqembi-iqlik-subcutaneous-initiation-dosi-d33ace08097ee0d5 https://app.biotechtracker.dev/events/alks-readout-2026-07-13-alixorexton-long-term-extension-interim-shows-sustained-4fc1491f870e380f https://app.biotechtracker.dev/events/sny-approval-2026-07-10-fda-approves-subcutaneous-sarclisa-escena-first-anticanc-e8eacaa4cd30ae3d https://app.biotechtracker.dev/events/pfe-approval-2026-07-10-fda-approves-padcev-plus-keytruda-before-and-after-surge-f5ccd2dbc977c75d https://app.biotechtracker.dev/events/gsk-readout-2026-07-10-phase-iii-artemis-008-met-overall-survival-endpoint-for-r-c6fc0aa44bcb875d https://app.biotechtracker.dev/events/ions-readout-2026-07-09-phase-3-cardio-ttransform-missed-primary-endpoint-for-ep-6e7532cfa5361b18 https://app.biotechtracker.dev/events/azn-readout-2026-07-09-phase-3-cardio-ttransform-eplontersen-missed-primary-endp-c418522a4e0d944f https://app.biotechtracker.dev/events/crsp-approval-2026-07-02-fda-approves-casgevy-for-sickle-cell-and-beta-thalassem-5c7863ca16cb0378 https://app.biotechtracker.dev/events/vrtx-approval-2026-07-01-fda-approves-expanded-casgevy-use-down-to-age-2-in-scd-ba87bbc4d5e973a2 https://app.biotechtracker.dev/events/srpt-other-2026-06-30-fda-accepts-amondys-45-and-vyondys-53-sndas-pdufa-date-feb-e57971ed54e6cda8 https://app.biotechtracker.dev/events/sny-readout-2026-06-30-nexviazyme-met-all-primary-and-secondary-endpoints-in-inf-29bf4593c22d2ec0 https://app.biotechtracker.dev/events/uthr-approval-2026-06-29-fda-approves-lungfx-device-for-centralized-ex-vivo-lung-3b25cb1ae863758a https://app.biotechtracker.dev/events/abbv-readout-2026-06-29-phase-3-epcore-dlbcl-4-met-primary-endpoint-60-cut-in-pr-309d2bcc16b67701 https://app.biotechtracker.dev/events/acad-other-2026-06-26-chmp-positive-opinion-recommends-eu-approval-of-daybu-trof-a89e38deee82c357 https://app.biotechtracker.dev/events/abbv-approval-2026-06-26-fda-approves-skyrizi-for-pediatric-plaque-psoriasis-and-a3d7fa4c49d180c7 https://app.biotechtracker.dev/events/kymr-other-2026-06-25-broaden2-enrollment-done-early-kt-621-topline-pulled-forwa-86ef630a6220a8fc https://app.biotechtracker.dev/events/vktx-other-2026-06-24-viking-starts-phase-1-study-of-amylin-agonist-vk3019-in-ob-6c94ebc884f08017 https://app.biotechtracker.dev/events/ions-approval-2026-06-24-fda-approves-tryngolza-olezarsen-for-severe-hypertrigly-47c56f3233143a5e https://app.biotechtracker.dev/events/gild-approval-2026-06-24-fda-approves-trodelvy-for-first-line-metastatic-triple-70546b3391dd93cb https://app.biotechtracker.dev/events/regn-other-2026-06-22-fda-accepts-cemdisiran-nda-under-priority-review-in-gmg-pd-63aef567cca538db https://app.biotechtracker.dev/events/pfe-readout-2026-06-22-phase-3-sigvie-002-missed-primary-endpoint-of-os-for-sigv-820fedf795d50e7c https://app.biotechtracker.dev/events/mrk-readout-2026-06-22-phase-3-atlas-uc-tulisokibart-met-primary-and-key-seconda-16c97c9de9355402 https://app.biotechtracker.dev/events/exel-readout-2026-06-22-stellar-303-missed-dual-primary-os-endpoint-in-non-liver-dc30700fc4ece044 https://app.biotechtracker.dev/events/arwr-approval-2026-06-22-ec-grants-eu-marketing-authorization-for-redemplo-ploza-ef4bc37da7315e92 https://app.biotechtracker.dev/events/mrna-adcomm-2026-06-18-fda-adcomm-votes-9-0-in-favor-of-mrna-1010-flu-vaccine-be-cf778ded97363103 https://app.biotechtracker.dev/events/alks-conference-2026-06-17-detailed-positive-vibrance-2-alixorexton-data-present-1331ca336a11fea9 https://app.biotechtracker.dev/events/jazz-conference-2026-06-16-jazz-presents-11-late-breaking-xywav-analyses-at-slee-52169715533dd6db https://app.biotechtracker.dev/events/tak-conference-2026-06-15-oveporexton-phase-3-firstlight-radiantlight-data-prese-47c80300bc36c411 https://app.biotechtracker.dev/events/nbix-conference-2026-06-15-two-year-phase-3-cahtalyst-pediatric-data-show-improv-399e4183178f73db https://app.biotechtracker.dev/events/halo-other-2026-06-15-halozyme-sees-zero-to-minimal-royalty-hit-from-cms-ipay-20-d3b1c9ca89de1173 https://app.biotechtracker.dev/events/gild-pdufa-2026-06-15-fda-accepts-once-weekly-oral-yeztugo-snda-for-hiv-prep-pdu-9eeaeb4a56f1ee3d https://app.biotechtracker.dev/events/azn-approval-2026-06-15-fda-approves-truqap-combination-for-pten-deficient-metas-1d56c51e8c464b92 https://app.biotechtracker.dev/events/lly-conference-2026-06-14-eha-2026-phase-3-bruin-cll-322-cut-progression-or-deat-2e67162201e8216d https://app.biotechtracker.dev/events/legn-conference-2026-06-14-eha-2026-late-breaker-lb2501-establishes-in-vivo-car-a82cd939ec5c56ad https://app.biotechtracker.dev/events/sny-approval-2026-06-13-fda-grants-tzield-accelerated-approval-in-newly-diagnose-98f771bcf5a470e6 https://app.biotechtracker.dev/events/rytm-conference-2026-06-13-endo-2026-positive-interim-6-month-phase-2-setmelanot-b9bd64e416f66a7d https://app.biotechtracker.dev/events/ntla-conference-2026-06-13-additional-positive-phase-3-haelo-data-at-eaaci-2026-58df18a8b0c38f3a https://app.biotechtracker.dev/events/mrk-approval-2026-06-12-fda-approves-keytruda-with-welireg-for-adjuvant-clear-ce-288b742374574e76 https://app.biotechtracker.dev/events/jazz-readout-2026-06-12-phase-3-lagoon-missed-overall-survival-endpoint-for-zepz-cb77366d09fd32ff https://app.biotechtracker.dev/events/ions-conference-2026-06-12-olezarsen-core-ole-liver-fat-data-at-nla-show-hepatic-4a85f85d64568ab3 https://app.biotechtracker.dev/events/vrtx-conference-2026-06-11-casgevy-pivotal-data-in-children-ages-5-11-at-eha-pub-82e5b1816c8af56f https://app.biotechtracker.dev/events/tak-readout-2026-06-11-zasocitinib-beats-deucravacitinib-on-primary-endpoint-in-0cc0e3e3699c21c0 https://app.biotechtracker.dev/events/sny-readout-2026-06-10-riliprubart-mobilize-phase-3-in-cidp-stopped-for-futility-4305541defc078c8 https://app.biotechtracker.dev/events/tgtx-readout-2026-06-09-positive-phase-1-briumvi-data-in-myasthenia-gravis-phase-f06874a705931a67 https://app.biotechtracker.dev/events/pfe-approval-2026-06-08-fda-approves-hympavzi-for-two-additional-hemophilia-a-or-c431d44232ee228a https://app.biotechtracker.dev/events/mrk-readout-2026-06-08-phase-3-keynote-d46-evoke-03-discontinued-after-pfs-misse-2a1cab0a015ab32f https://app.biotechtracker.dev/events/lly-conference-2026-06-08-ada-2026-foundayo-beat-oral-semaglutide-on-a1c-in-phas-575bf5815c8ceed2 https://app.biotechtracker.dev/events/gild-readout-2026-06-08-islend-1-and-islend-2-met-week-48-primary-endpoints-for-903cf3a695b4de34 https://app.biotechtracker.dev/events/nvo-conference-2026-06-07-cagrisema-reimagine-1-3-phase-3-results-presented-at-a-38498f992526131b https://app.biotechtracker.dev/events/amgn-conference-2026-06-07-repatha-cut-cv-events-29-in-high-risk-diabetes-subgro-d7a878a9c7efa651 https://app.biotechtracker.dev/events/lly-conference-2026-06-06-ada-2026-retatrutide-improved-weight-a1c-knee-oa-pain-f93dc36fd3baf22b https://app.biotechtracker.dev/events/vrtx-conference-2026-06-05-alyftrek-phase-3-data-in-children-ages-2-5-presented-2d9c93668f933249 https://app.biotechtracker.dev/events/tgtx-readout-2026-06-03-phase-1-subcutaneous-briumvi-pk-pd-de-risks-ongoing-phas-5e05e56223c6e389 https://app.biotechtracker.dev/events/mdgl-approval-2026-06-03-mhra-authorises-rezdiffra-resmetirom-for-mash-in-adults-d1de9d0e07fff93c https://app.biotechtracker.dev/events/iova-approval-2026-06-03-australia-s-tga-approves-amtagvi-for-previously-treated-50c528ca794b0eb3 https://app.biotechtracker.dev/events/argx-conference-2026-06-03-eular-2026-long-term-efgartigimod-data-in-myositis-an-2f05543421638eae https://app.biotechtracker.dev/events/pcvx-other-2026-06-02-first-participant-dosed-in-phase-1-study-of-vax-a1-for-gro-b968805ef0a231ff https://app.biotechtracker.dev/events/legn-readout-2026-06-02-lb2501-in-vivo-car-t-phase-1-100-orr-at-dose-level-2-in-2808f1ccba14d010 https://app.biotechtracker.dev/events/vrtx-other-2026-06-01-fda-accepts-povetacicept-bla-in-igan-pdufa-target-date-nov-b102d16ba51690f1 https://app.biotechtracker.dev/events/nvs-conference-2026-06-01-novartis-details-eular-2026-immunology-data-incl-cosen-34ab642037576a7f https://app.biotechtracker.dev/events/legn-conference-2026-06-01-asco-2026-lb2102-first-in-human-orr-28-6-in-sclc-new-82550c84c47db971 https://app.biotechtracker.dev/events/iova-other-2026-06-01-fda-clears-ind-for-il-12-tethered-til-therapy-iov-5001-95ad2a1473daed51 https://app.biotechtracker.dev/events/amgn-approval-2026-06-01-european-commission-approves-imdylltra-for-extensive-st-5e20200be6c7d5f1 https://app.biotechtracker.dev/events/smmt-readout-2026-05-31-phase-3-harmoni-6-met-os-endpoint-vs-tislelizumab-in-1l-1184c489cf27dd18 https://app.biotechtracker.dev/events/pfe-conference-2026-05-31-asco-2026-braftovi-regimen-nearly-doubled-median-pfs-i-ceab803be05fd9bb https://app.biotechtracker.dev/events/jnj-conference-2026-05-31-phase-3-proteus-final-analysis-perioperative-erleada-c-002a92e027019260 https://app.biotechtracker.dev/events/incy-conference-2026-05-30-phase-3-frontmind-tafasitamab-combo-cut-progression-o-faaa311a52e632a6 https://app.biotechtracker.dev/events/exel-conference-2026-05-30-cabinet-asco-2026-subgroup-cabometyx-improved-pfs-in-793bbb1743bb8984 https://app.biotechtracker.dev/events/bntx-conference-2026-05-30-pumitamig-rosetta-lung-02-interim-phase-2-shows-high-05b88a2714378c78 https://app.biotechtracker.dev/events/jnj-approval-2026-05-28-fda-approves-tremfya-label-expansion-for-inhibition-of-s-bd7e1e6f998f4757 https://app.biotechtracker.dev/events/ions-conference-2026-05-28-partner-gsk-s-phase-3-b-well-trials-show-19-functiona-2a153863b44d290f https://app.biotechtracker.dev/events/tgtx-readout-2026-05-27-phase-3-enhance-met-primary-endpoint-single-day-1-briumv-f6788621c0ad9f3c https://app.biotechtracker.dev/events/jazz-conference-2026-05-27-phase-3-herizon-gea-01-ziihera-results-published-in-n-4e09c76655ae9b4a https://app.biotechtracker.dev/events/abbv-approval-2026-05-27-fda-approves-decnupaz-pivekimab-sunirine-for-bpdcn-4d0298ed09fe84be https://app.biotechtracker.dev/events/nvs-conference-2026-05-26-novartis-flags-late-breaking-phase-iii-kidney-data-for-a9da082dda6f529f https://app.biotechtracker.dev/events/gild-approval-2026-05-22-fda-grants-hepcludex-accelerated-approval-first-us-trea-53b588b3e236939e https://app.biotechtracker.dev/events/lly-readout-2026-05-21-phase-3-triumph-1-retatrutide-delivered-up-to-28-3-weight-24b14f60373bc3dc https://app.biotechtracker.dev/events/dnli-readout-2026-05-21-phase-2b-luma-missed-primary-and-secondary-endpoints-bii-6e31023ae0d64d49 https://app.biotechtracker.dev/events/mdgl-conference-2026-05-20-madrigal-to-present-phase-3-rezdiffra-analyses-at-eas-fddaa1dd6777e938 https://app.biotechtracker.dev/events/imvt-other-2026-05-20-immunovant-discontinues-batoclimab-across-all-indications-54104f422dff64ec https://app.biotechtracker.dev/events/bmrn-readout-2026-05-20-phase-3-canopy-hch-3-met-primary-endpoint-voxzogo-2-33-c-5f8bbebafa352f5f https://app.biotechtracker.dev/events/uthr-conference-2026-05-18-teton-1-full-results-published-in-nejm-and-presented-1ee60fbf7a54b009 https://app.biotechtracker.dev/events/mrk-readout-2026-05-18-phase-3-trofuse-005-met-os-and-pfs-endpoints-for-sac-tmt-9a3ba7a6504ae4e8 https://app.biotechtracker.dev/events/krys-approval-2026-05-18-uk-mhra-approves-vyjuvek-for-dystrophic-epidermolysis-b-e75c61e8cbf01d3a https://app.biotechtracker.dev/events/bmrn-readout-2026-05-18-phase-3-energy-3-bmn-401-met-ppi-co-primary-but-missed-r-db2d816c1152a5b1 https://app.biotechtracker.dev/events/beam-conference-2026-05-18-beam-302-aatd-phase-1-2-topline-data-presented-at-ats-eb0df87a283a9f13 https://app.biotechtracker.dev/events/uthr-conference-2026-05-17-full-advance-outcomes-ralinepag-results-presented-at-eaa32df1aba5dffc https://app.biotechtracker.dev/events/regn-readout-2026-05-15-phase-3-fianlimab-combo-missed-pfs-primary-endpoint-in-1-49ba582bba220b8d https://app.biotechtracker.dev/events/biib-readout-2026-05-14-phase-2-celia-missed-primary-endpoint-but-cut-tau-and-sl-81cb408c28eb4f8c https://app.biotechtracker.dev/events/azn-readout-2026-05-14-phase-3-volga-imfinzi-plus-neoadjuvant-ev-improved-efs-an-352240aea59db7d7 https://app.biotechtracker.dev/events/vktx-conference-2026-05-12-oral-vk2735-phase-2-data-at-eco-2026-up-to-12-2-weigh-4f5bdb8503241c47 https://app.biotechtracker.dev/events/gern-conference-2026-05-12-first-real-world-rytelo-study-in-lr-mds-to-be-present-4d2e398e19ed6c95 https://app.biotechtracker.dev/events/alny-conference-2026-05-12-helios-b-analyses-at-heart-failure-2026-show-consiste-5ffd435acd7f1f0e https://app.biotechtracker.dev/events/alks-readout-2026-05-12-phase-3-revitalyz-met-primary-endpoint-for-lumryz-in-idi-e0dcd38e0e87c2d7 https://app.biotechtracker.dev/events/cytk-conference-2026-05-11-new-sequoia-hcm-maple-hcm-and-forest-hcm-analyses-sho-c0ca474ab05fc57a https://app.biotechtracker.dev/events/halo-approval-2026-05-08-fda-expands-vyvgart-vyvgart-hytrulo-label-to-all-gmg-se-c50817b36188fd1c https://app.biotechtracker.dev/events/argx-approval-2026-05-08-fda-approves-vyvgart-label-expansion-to-all-adult-gmg-s-05e5ddb8248b6d2e https://app.biotechtracker.dev/events/ptct-other-2026-05-07-fda-feedback-sets-new-open-label-vatiquinone-registration-ff01bfb1255c4f37 https://app.biotechtracker.dev/events/rxrx-readout-2026-05-06-rec-4881-phase-2-in-fap-53-median-polyp-burden-cut-at-we-15b418e682d84856 https://app.biotechtracker.dev/events/cytk-readout-2026-05-05-phase-3-acacia-hcm-met-both-primary-endpoints-in-non-obs-2aef825ee609f3c8 https://app.biotechtracker.dev/events/halo-readout-2026-05-04-partner-takeda-pivotal-phase-2-3-of-tak-881-met-primary-44ddb7e72cf27c7e https://app.biotechtracker.dev/events/azn-adcomm-2026-05-01-fda-odac-votes-7-1-that-truqap-has-favourable-benefit-risk-721dbd14fa9db905 https://app.biotechtracker.dev/events/arwr-approval-2026-05-01-australia-s-tga-approves-redemplo-plozasiran-for-fcs-0676da37d4db6523 https://app.biotechtracker.dev/events/smmt-readout-2026-04-30-harmoni-3-squamous-interim-pfs-misses-bar-idmc-recommend-5e6bc4bafcdfac52 https://app.biotechtracker.dev/events/krys-conference-2026-04-30-krystal-to-present-kb407-coral-1-interim-cystic-fibro-7c2cb449d47015c6 https://app.biotechtracker.dev/events/axsm-approval-2026-04-30-fda-approves-auvelity-for-agitation-associated-with-alz-2c1b513597a43ba2 https://app.biotechtracker.dev/events/pfe-readout-2026-04-29-elrexfio-magnetismm-5-ph3-met-primary-endpoint-of-pfs-in-1118e68583c85a04 https://app.biotechtracker.dev/events/gild-pdufa-2026-04-29-fda-grants-priority-review-to-bictegravir-lenacapavir-nda-5d35453acff845b6 https://app.biotechtracker.dev/events/ptct-readout-2026-04-28-positive-month-24-pivot-hd-interim-votoplam-slowed-hd-pr-30abcc1a74cea814 https://app.biotechtracker.dev/events/gsk-pdufa-2026-04-28-fda-grants-bepirovirsen-priority-review-and-breakthrough-st-2a4cb74eb6d84ddb https://app.biotechtracker.dev/events/ntla-readout-2026-04-27-phase-3-haelo-met-primary-endpoint-87-cut-in-hae-attacks-c8e750e2e083dfd6 https://app.biotechtracker.dev/events/jnj-approval-2026-04-27-fda-approves-caplyta-snda-for-relapse-prevention-in-schi-dcc8be49d812dd8a https://app.biotechtracker.dev/events/jazz-other-2026-04-27-fda-accepts-ziihera-1l-gea-sbla-with-priority-review-pdufa-b8fe3558111df4ab https://app.biotechtracker.dev/events/amgn-other-2026-04-27-fda-cder-proposes-withdrawal-of-tavneos-over-efficacy-and-9c1a27e89246cc9b https://app.biotechtracker.dev/events/arwr-other-2026-04-24-chmp-positive-opinion-recommends-eu-approval-of-redemplo-p-d34e436c82f1c774 https://app.biotechtracker.dev/events/regn-approval-2026-04-23-fda-grants-accelerated-approval-to-otarmeni-for-otof-ge-9173f06c8c95c0e7 https://app.biotechtracker.dev/events/abbv-crl-2026-04-23-crl-for-trenibotulinumtoxine-bla-over-manufacturing-process-482d769fb7c8af54 https://app.biotechtracker.dev/events/sny-approval-2026-04-22-fda-expands-tzield-to-children-as-young-as-one-to-delay-65fb633483371800 https://app.biotechtracker.dev/events/sny-pdufa-2026-04-22-fda-extends-sarclisa-subcutaneous-us-action-date-by-three-m-3c3d384ffaf65f0c https://app.biotechtracker.dev/events/mrk-readout-2026-04-21-phase-3-litespark-012-missed-dual-primary-endpoints-of-pf-181080cc4f5043ab https://app.biotechtracker.dev/events/ions-conference-2026-04-21-zilganersen-pivotal-aan-2026-data-reinforce-benefit-p-a0f4d3dad4b8adab https://app.biotechtracker.dev/events/nvo-readout-2026-04-20-etavopivat-met-both-co-primary-endpoints-in-phase-3-hibis-5c85e48e14eda419 https://app.biotechtracker.dev/events/nvax-readout-2026-04-18-nuvaxovid-beat-mnexspike-on-tolerability-in-phase-4-head-a5405991d35bec86 https://app.biotechtracker.dev/events/argx-conference-2026-04-18-aan-2026-adapt-oculus-shows-vyvgart-benefit-in-ocular-fd282ea316a2bc44 https://app.biotechtracker.dev/events/bntx-readout-2026-04-11-trastuzumab-pamirtecan-met-primary-orr-endpoint-in-her2-ea23e9cf9a3e385d https://app.biotechtracker.dev/events/insm-readout-2026-04-07-phase-2b-cedar-failed-insmed-drops-brensocatib-in-hidrad-62da6d409e1f6564 https://app.biotechtracker.dev/events/amgn-readout-2026-04-06-phase-3-subcutaneous-tepezza-met-primary-endpoint-in-thy-a6190a6f46ba3690 https://app.biotechtracker.dev/events/dnli-other-2026-04-03-takeda-terminates-dnl593-collaboration-rights-revert-to-de-f351af073483bfce https://app.biotechtracker.dev/events/regn-approval-2026-04-02-fda-approves-eylea-hd-dosing-intervals-up-to-every-20-w-e6d0560bd7b82d7d https://app.biotechtracker.dev/events/rare-other-2026-04-02-fda-accepts-resubmitted-ux111-bla-for-sanfilippo-a-pdufa-s-0c5cdcc5198b2740 https://app.biotechtracker.dev/events/imvt-readout-2026-04-02-two-phase-3-batoclimab-studies-missed-primary-endpoint-i-d1f125b4f00f34e4 https://app.biotechtracker.dev/events/lly-approval-2026-04-01-fda-approves-foundayo-orforglipron-first-oral-glp-1-pill-2446245b86e8b8dd https://app.biotechtracker.dev/events/beam-other-2026-04-01-beacon-phase-1-2-risto-cel-sickle-cell-data-published-in-n-f9b55b1296315d8c https://app.biotechtracker.dev/events/amgn-other-2026-03-31-fda-flags-fatal-liver-injury-cases-with-amgen-s-tavneos-6323e8d148d3fc57 https://app.biotechtracker.dev/events/uthr-readout-2026-03-30-phase-3-teton-1-met-primary-endpoint-for-tyvaso-in-ipf-1-b916410ca67ad60e https://app.biotechtracker.dev/events/bmy-conference-2026-03-30-acc-26-phase-3-scout-hcm-showed-camzyos-benefit-in-ado-7571e111f2701962 https://app.biotechtracker.dev/events/alny-conference-2026-03-30-vutrisiran-helios-b-and-zilebesiran-data-presented-at-61e6e02aff5b16e6 https://app.biotechtracker.dev/events/tak-conference-2026-03-28-zasocitinib-phase-3-psoriasis-data-presented-as-aad-20-1f622481afe302bb https://app.biotechtracker.dev/events/sny-conference-2026-03-28-positive-amlitelimab-phase-3-atopic-dermatitis-data-pr-51aab4f93997ff5d https://app.biotechtracker.dev/events/amgn-conference-2026-03-28-repatha-cut-first-major-cv-events-31-in-high-risk-pat-4f069887e0180204 https://app.biotechtracker.dev/events/azn-readout-2026-03-27-phase-3-oberon-and-titania-tozorakimab-met-primary-endpoi-f070722c58ec7e9e https://app.biotechtracker.dev/events/vktx-other-2026-03-26-phase-3-vanquish-2-of-vk2735-completes-enrollment-1-000-pa-2706d464abdd7fbf https://app.biotechtracker.dev/events/rytm-other-2026-03-26-positive-chmp-opinion-for-imcivree-in-acquired-hypothalami-82cd10a777853493 https://app.biotechtracker.dev/events/srpt-readout-2026-03-25-first-sirna-clinical-data-in-fshd1-and-dm1-show-knockdow-2de1afbc83c010a7 https://app.biotechtracker.dev/events/dnli-approval-2026-03-25-fda-grants-accelerated-approval-of-avlayah-for-hunter-s-eb23c4117af63db4 https://app.biotechtracker.dev/events/beam-readout-2026-03-25-beam-302-phase-1-2-update-in-aatd-60-mg-selected-for-piv-ad9d776772143099 https://app.biotechtracker.dev/events/bntx-conference-2026-03-24-gotistobart-phase-3-stage-1-cut-risk-of-death-54-in-s-e75f07e7ba796203 https://app.biotechtracker.dev/events/pfe-readout-2026-03-23-phase-3-valor-lyme-vaccine-vla15-showed-73-2-efficacy-vs-0bff6cc0b472dab6 https://app.biotechtracker.dev/events/pfe-readout-2026-03-23-lyme-vaccine-pf-07307405-valor-ph3-topline-73-2-efficacy-c4bb8fb9441dd262 https://app.biotechtracker.dev/events/pcvx-other-2026-03-23-opus-1-and-opus-2-phase-3-enrollment-complete-opus-1-topli-14a9d00e8f45571c https://app.biotechtracker.dev/events/insm-readout-2026-03-23-phase-3b-encore-met-primary-and-all-key-secondary-endpoi-f443495a1fb17c47 https://app.biotechtracker.dev/events/bmy-approval-2026-03-20-fda-approves-opdivo-plus-avd-for-untreated-stage-iii-iv-4e1dfbf7d8c59fa3 https://app.biotechtracker.dev/events/rytm-approval-2026-03-19-fda-approves-imcivree-for-acquired-hypothalamic-obesity-21f6e9234c9b4f9a https://app.biotechtracker.dev/events/pfe-readout-2026-03-19-phase-3-talapro-3-met-primary-endpoint-of-rpfs-in-metasta-74223e80c582d9aa https://app.biotechtracker.dev/events/nvo-approval-2026-03-19-fda-approves-wegovy-hd-semaglutide-7-2-mg-with-20-7-mean-611ef4592af3a975 https://app.biotechtracker.dev/events/pcvx-other-2026-03-18-vax-31-adult-phase-1-2-data-published-in-lancet-infectious-6c3f9bf2c25c1c1d https://app.biotechtracker.dev/events/jnj-approval-2026-03-18-fda-approves-icotyde-icotrokinra-first-oral-il-23-recept-bcb78e1efd4ccc89 https://app.biotechtracker.dev/events/rytm-readout-2026-03-16-phase-3-emanate-missed-primary-endpoint-in-all-four-subs-f75ab75e9364ce79 https://app.biotechtracker.dev/events/bmrn-other-2026-03-16-voxzogo-phase-2-trials-in-turner-shox-and-acan-halted-afte-922f708e05db924c https://app.biotechtracker.dev/events/nvs-approval-2026-03-13-fda-approves-cosentyx-for-adolescents-12-with-hidradenit-8aa9cd759caf9d24 https://app.biotechtracker.dev/events/gsk-approval-2026-03-13-fda-expands-arexvy-label-to-at-risk-adults-aged-18-49-9cb89cc6495bc5fb https://app.biotechtracker.dev/events/rare-readout-2026-03-12-phase-3-enh3ance-met-primary-endpoint-dtx301-cut-24-hour-1e5494e9e932ac7e https://app.biotechtracker.dev/events/vrtx-readout-2026-03-09-phase-3-rainier-interim-met-primary-and-all-secondary-en-354249ccabee7f2a https://app.biotechtracker.dev/events/incy-crl-2026-03-06-crl-for-zynyz-in-metastatic-nsclc-over-third-party-fill-fini-123a36c878082da6 https://app.biotechtracker.dev/events/halo-approval-2026-03-06-fda-approves-tecvayli-darzalex-faspro-enhanze-in-r-r-mu-54118a7fd88d705a https://app.biotechtracker.dev/events/argx-conference-2026-03-06-argenx-to-present-phase-3-adapt-oculus-and-seron-data-3d2c47d5afaabdb0 https://app.biotechtracker.dev/events/jnj-approval-2026-03-05-fda-approves-tecvayli-plus-darzalex-faspro-in-second-lin-1a6854adfad73c8e https://app.biotechtracker.dev/events/uthr-readout-2026-03-02-phase-3-advance-outcomes-met-primary-endpoint-ralinepag-7a57a1c451cec766 https://app.biotechtracker.dev/events/tak-pdufa-2026-03-02-fda-accepts-rusfertide-nda-with-priority-review-pdufa-set-f-705348e8b448573e https://app.biotechtracker.dev/events/acad-other-2026-03-02-chmp-adopts-negative-opinion-on-trofinetide-for-rett-syndr-237e8dc475df6704 https://app.biotechtracker.dev/events/abbv-readout-2026-03-02-phase-3-affirm-met-endpoints-for-skyrizi-subcutaneous-in-39615c9ad1754a9e